Clinical Trials Logo

Nerve Sheath Neoplasms clinical trials

View clinical trials related to Nerve Sheath Neoplasms.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06277154 Not yet recruiting - Leiomyosarcoma Clinical Trials

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

Start date: February 2024
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma.

NCT ID: NCT06222203 Not yet recruiting - Neurofibromatosis 1 Clinical Trials

Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

Start date: June 26, 2024
Phase:
Study type: Observational

Background: Neurofibromatosis type 1 (NF1) is a genetic disease that can cause many symptoms. About half of people with NF1 will develop benign (noncancerous) tumors along nerves in the skin, brain, and other parts of the body. Sometimes, though, these tumors can become cancerous. Researchers do not yet know how to predict which tumors will become cancerous. Objective: To test a new method for predicting which benign NF1 tumors will become cancerous. Eligibility: People aged 3 years and older with a clinical or genetic diagnosis of NF1. Design: - Participants will be screened with a review of their medical history. All participants will have a baseline visit. They will have bood tests and imaging scans. They will have a physical exam. They will answer questions about their family history. Participants aged 8 years and older will take tests of their thinking skills and their emotional health. - Some participants may be asked to undergo more tests. These may include another type of imaging scan and a biopsy: A small sample of tissue may be removed from the tumor. - Participants will be divided into two groups: those believed to be at low risk and those believed to be at high risk of developing cancer. - Participants in the high-risk group will be asked to return for their next visit in 1 month to 3 years. - Participants in the low-risk group will be asked to return for their next visit in 6 months to 5 years. - Participants may also have follow-up visits by phone throughout the study. They will be in the study for 10 years.

NCT ID: NCT06041347 Not yet recruiting - Endometriosis Clinical Trials

Learning Curve for the Visualization of Sacral Plexus on TVS

PlexUS
Start date: October 1, 2023
Phase:
Study type: Observational

The purpose of this prospective study was to evaluate the learning curve of TVUS (transvaginal ultrasound) for the visualization of sacral nerve roots and sacral plexus on gynecological transvaginal ultrasound. The investigators aim to evaluate to evaluate the number needed to gain competence or to review the level of competence.

NCT ID: NCT05445271 Not yet recruiting - Clinical trials for Intubation Complication

Optic Nerve Sheath Diameter in Pediatric Patients

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

Endotracheal intubation and laryngeal mask are generally applied to secure the airway during general anesthesia. There is a widespread opinion among anesthesiologists that endotracheal intubation increases intracranial pressure. Since there were no non-invasive methods measuring intracranial pressure in the past, adequate studies on this subject could not be done. With this measurement, we aimed to show whether ETT or LMA applications have effects on intracranial pressure.

NCT ID: NCT03105258 Not yet recruiting - Clinical trials for Neurofibromatosis Type 1

Selumetinib Pilot Study for Cutaneous Neurofibromas

Start date: May 1, 2017
Phase: Phase 2
Study type: Interventional

This is a small study of the oral MEK1/2 inhibitor, selumetinib, to evaluate the potential utility of selumetinib in individuals ≥ 18 years old with Neurofibromatosis 1 (NF1) and cutaneous neurofibromas (cNFs). The study aims to determine whether selumetinib will result in shrinkage of existing cutaneous neurofibromas and if it prevents or delays the development of new cutaneous neurofibromas.